Replies to post #64011 on Biotech Values

[rkrw]

Baxter is huge, I can't imagine selling generic heparin is much more than a rounding error for them.

[DewDiligence]

Amusingly, Oppenheimer analyst Balaji Gandhi cites lower heparin pricing as a motivation for the APPX buyout by Fresenius:

http://www.reuters.com/article/marketsNews/idINL0765539120080707